Histone deacetylases (HDACs) are enzymes that catalyze the deacetylation of lysine residues located in the NH2 terminal tails of core histones, which is associated with transcriptional silencing. There are 18 known human histone deacetylases, grouped into four classes based on the structure of their accessory domains. Class I (HDACs 1-3 and 8), II (HDACs 4-7, 9, and 10), and IV (HDAC 11) enzymes are Zn2+-dependent enzymes and are called HDACs, while class III enzymes (also known as sirtuins) are defined by their dependency on NAD+.
Histone deacetylase inhibitors (HDACis) are emerging as a new class of anticancer drugs and have been shown to alter gene transcription and exert antitumor effects such as growth arrest, differentiation, apoptosis, and inhibition of tumor angiogenesis. Read more…